MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
Associated Therapies
-

Olmesartan Medoxomil and Diabetic Nephropathy

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Diabetic Nephropathy
Proteinuria
Renal Disease
First Posted Date
2006-08-15
Last Posted Date
2006-10-09
Lead Sponsor
Sankyo Pharma Gmbh
Target Recruit Count
300
Registration Number
NCT00362960

Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy

Not Applicable
Completed
Conditions
Type 2 Diabetes
Diabetic Nephropathy
First Posted Date
2006-08-07
Last Posted Date
2006-08-07
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
25
Registration Number
NCT00361023

Renoprotection in Early Diabetic Nephropathy in Pima Indians

Phase 3
Completed
Conditions
Diabetic Nephropathy
Interventions
Drug: Placebo
Drug: Losartan
First Posted Date
2006-06-21
Last Posted Date
2021-03-25
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
170
Registration Number
NCT00340678
Locations
🇺🇸

NIDDK, Phoenix, Phoenix, Arizona, United States

Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency

Not Applicable
Terminated
Conditions
Renal Insufficiency,Chronic
Disease Progression
Proteinuria
Dose-Response Relationship,Drug
ACE Inhibitor
Angiotensin II Type 1 Receptor Blockers
First Posted Date
2006-06-20
Last Posted Date
2006-06-20
Lead Sponsor
Southern Medical University, China
Registration Number
NCT00338091
Locations
🇨🇳

Renal Division, Nanfang Hospital,Southern Medical University, Guangzhou, Guangdong, China

Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C

Phase 4
Completed
Conditions
Chronic Hepatitis C
Liver Fibrosis
First Posted Date
2006-03-03
Last Posted Date
2007-11-22
Lead Sponsor
Hospital Clinic of Barcelona
Target Recruit Count
20
Registration Number
NCT00298714

The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant

Phase 4
Completed
Conditions
Liver Transplant Recipients
First Posted Date
2006-01-12
Last Posted Date
2012-01-06
Lead Sponsor
Mayo Clinic
Target Recruit Count
62
Registration Number
NCT00275639
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Treatment of Supine Hypertension in Autonomic Failure

First Posted Date
2005-09-22
Last Posted Date
2017-10-13
Lead Sponsor
Vanderbilt University
Target Recruit Count
152
Registration Number
NCT00223717
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Phase 4
Completed
Conditions
Metabolic Syndrome
Hypertension
Insulin Resistance
First Posted Date
2005-09-16
Last Posted Date
2005-12-23
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
60
Registration Number
NCT00185094

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

Phase 4
Completed
Conditions
Hypertension
Diabetic Nephropathies
First Posted Date
2005-09-15
Last Posted Date
2023-12-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
860
Registration Number
NCT00168857
Locations
🇲🇽

Fracc. Magallanes, Acapulco Guerrero, Mexico

🇺🇸

VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States

🇹🇭

Pramongkutklao Hospital, Bangkok, Thailand

and more 62 locations

Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension

Phase 2
Withdrawn
Conditions
Hypertension
Interventions
First Posted Date
2005-09-09
Last Posted Date
2012-07-06
Lead Sponsor
University of Erlangen-Nürnberg Medical School
Registration Number
NCT00152633
Locations
🇩🇪

CRC, Med. Klinik 4, University of Erlangen-Nürnberg, Erlangen, Germany

© Copyright 2025. All Rights Reserved by MedPath